Pine Valley Investments Ltd Liability Co Has $687,000 Stock Holdings in Solventum Co. (NYSE:SOLV)

Pine Valley Investments Ltd Liability Co decreased its position in shares of Solventum Co. (NYSE:SOLV) by 51.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,394 shares of the company’s stock after selling 11,195 shares during the quarter. Pine Valley Investments Ltd Liability Co’s holdings in Solventum were worth $687,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of SOLV. International Assets Investment Management LLC lifted its stake in shares of Solventum by 5,118.4% in the 3rd quarter. International Assets Investment Management LLC now owns 129,261 shares of the company’s stock valued at $9,012,000 after purchasing an additional 126,784 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Solventum by 175.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 38,429 shares of the company’s stock valued at $2,597,000 after purchasing an additional 24,464 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Solventum by 22.3% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 47,922 shares of the company’s stock valued at $3,341,000 after purchasing an additional 8,730 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in shares of Solventum by 124.5% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 45,626 shares of the company’s stock valued at $3,055,000 after purchasing an additional 25,304 shares during the period. Finally, State of Alaska Department of Revenue lifted its stake in shares of Solventum by 7.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 16,075 shares of the company’s stock valued at $1,120,000 after purchasing an additional 1,085 shares during the period.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Morgan Stanley increased their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Bank of America upped their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday. Mizuho started coverage on shares of Solventum in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective for the company. Finally, Piper Sandler upped their price objective on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $71.86.

Solventum Stock Performance

SOLV stock opened at $83.83 on Thursday. The stock has a 50-day moving average price of $71.92 and a two-hundred day moving average price of $69.63. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.